MD Anderson Cancer Centre

Late clinical-stage nanomedicine company, Nanobiotix, has announced its cooperation with the University of Texas MD Anderson Cancer Center to run immunotherapeutic pre-clinical research combining NBTXR3 — the company’s lead product — with Nivolumab. Read more


Pharma companies have been teaming up in the fight against cancer. EPM lists the top 5 cancer fighting collaborations Read more


Kymab and MD Anderson Cancer Centre have announced a strategic cancer drug discovery and development alliance Read more